Section 6 of 6
References
209 sources
- ADARx Pharmaceuticals prospectus (2026) (opens in a new tab)
- Adatia et al. (2026) (opens in a new tab)
- Anderson et al. (2025a) (opens in a new tab)
- Anderson et al. (2025b) (opens in a new tab)
- Anderson et al. (2026a) (opens in a new tab)
- Anderson et al. (2026b) (opens in a new tab)
- Anderson et al. (2026c) (opens in a new tab)
- Arora et al. (2023) (opens in a new tab)
- Aygören-Pürsün et al. (2014) (opens in a new tab)
- Aygören-Pürsün et al. (2016) (opens in a new tab)
- Aygören-Pürsün et al. (2026a) (opens in a new tab)
- Aygören-Pürsün et al. (2026b) (opens in a new tab)
- Banta et al. (2011) (opens in a new tab)
- Bernstein et al. (2019) (opens in a new tab)
- Bernstein et al. (2025) (opens in a new tab)
- Betschel et al. (2024) (opens in a new tab)
- Betschel et al. (2025) (opens in a new tab)
- Betschel et al. (2026) (opens in a new tab)
- Blasco et al. (2013) (opens in a new tab)
- Bork et al. (2003) (opens in a new tab)
- Bork et al. (2006) (opens in a new tab)
- Bork et al. (2012) (opens in a new tab)
- Bui et al. (2026) (opens in a new tab)
- Busse et al. (2021) (opens in a new tab)
- Busse et al. (2026) (opens in a new tab)
- Buttgereit et al. (2025) (opens in a new tab)
- Caballero et al. (2014) (opens in a new tab)
- California HCAI five-year WAC increase history (2026) (opens in a new tab)
- California HCAI prescription drugs introduced to market (2019) (opens in a new tab)
- California HCAI prescription drugs introduced to market (2020) (opens in a new tab)
- California HCAI prescription drugs introduced to market (2021) (opens in a new tab)
- California HCAI prescription drugs introduced to market (2025) (opens in a new tab)
- California HCAI prescription drugs introduced to market (2026) (opens in a new tab)
- California HCAI WAC increase data (2024) (opens in a new tab)
- California HCAI WAC increase data (2025) (opens in a new tab)
- California HCAI WAC increase data (2026) (opens in a new tab)
- Cancian et al. (2025) (opens in a new tab)
- Castaldo et al. (2021) (opens in a new tab)
- Castaldo et al. (2025) (opens in a new tab)
- Christiansen et al. (2015) (opens in a new tab)
- Christiansen et al. (2023) (opens in a new tab)
- Christiansen et al. (2025a) (opens in a new tab)
- Christiansen et al. (2025b) (opens in a new tab)
- Christiansen et al. (2026) (opens in a new tab)
- Cicardi et al. (2010a) (opens in a new tab)
- Cicardi et al. (2010b) (opens in a new tab)
- Cigna Ekterly drug quantity management policy (2026) (opens in a new tab)
- Cigna Ekterly prior authorization policy (2026) (opens in a new tab)
- ClinicalTrials.gov NCT04618211 (opens in a new tab)
- ClinicalTrials.gov NCT04618211 API record (opens in a new tab)
- ClinicalTrials.gov NCT05396105 (opens in a new tab)
- ClinicalTrials.gov NCT06343779 (opens in a new tab)
- ClinicalTrials.gov NCT07759141 (opens in a new tab)
- CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
- CMS Medicare Part B payment limit file (2026) (opens in a new tab)
- CMS Medicare Part D Spending by Drug (2026) (opens in a new tab)
- Cohn et al. (2023) (opens in a new tab)
- Cohn et al. (2025) (opens in a new tab)
- Cohn et al. (2026) (opens in a new tab)
- CountyCare acute HAE products guideline (2026) (opens in a new tab)
- Crabbé et al. (2021) (opens in a new tab)
- Craig et al. (2009) (opens in a new tab)
- Craig et al. (2021) (opens in a new tab)
- Craig et al. (2026a) (opens in a new tab)
- Craig et al. (2026b) (opens in a new tab)
- CSL Behring (2022) (opens in a new tab)
- CSL Behring BERINERT prescribing information (2021) (opens in a new tab)
- CTIS.eu 2023-506305-18-01 (opens in a new tab)
- CTIS.eu 2024-514713-35-00 (opens in a new tab)
- Cycle SAJAZIR prescribing information (2024) (opens in a new tab)
- Danielsson et al. (2025) (opens in a new tab)
- Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
- Derendorf et al. (2020) (opens in a new tab)
- EMA orphan designation EU/3/25/3040 (2025) (opens in a new tab)
- EMA paediatric investigation plan decision P/0411/2023 (2023) (opens in a new tab)
- EMA paediatric investigation plan modification EMA/PE/0000227462 (2025) (opens in a new tab)
- EU Clinical Trials Register 2021-006906-58 (opens in a new tab)
- Farkas et al. (2025) (opens in a new tab)
- Farkas et al. (2026) (opens in a new tab)
- FDA (2022) (opens in a new tab)
- FDA ANDEMBRY prescribing information (2025) (opens in a new tab)
- FDA DAWNZERA prescribing information (2025) (opens in a new tab)
- FDA Drug Trials Snapshot EKTERLY (opens in a new tab)
- FDA ORLADEYO prescribing information (2026) (opens in a new tab)
- FDA Orphan Drug Designations and Approvals (2022) (opens in a new tab)
- FDA TAKHZYRO prescribing information (2026) (opens in a new tab)
- Federici et al. (2018) (opens in a new tab)
- Fijen et al. (2023) (opens in a new tab)
- Fisch et al. (2025) (opens in a new tab)
- G-BA sebetralstat resolution justification (2026) (opens in a new tab)
- Gallop et al. (2026) (opens in a new tab)
- Groen et al. (2021) (opens in a new tab)
- Grover et al. (2022) (opens in a new tab)
- Grumach et al. (2026) (opens in a new tab)
- Guan et al. (2024) (opens in a new tab)
- HAS EKTERLY transparency committee opinion (2026) (opens in a new tab)
- Henao et al. (2016) (opens in a new tab)
- Heuring et al. (2026) (opens in a new tab)
- Hummel et al. (2026) (opens in a new tab)
- ICER final evidence report (2018) (opens in a new tab)
- Intellia Therapeutics AAAAI poster (2026) (opens in a new tab)
- Jacobs et al. (2025) (opens in a new tab)
- KalVista EKTERLY prescribing information (2025) (opens in a new tab)
- KalVista Pharmaceuticals Colorado WAC disclosure (2026) (opens in a new tab)
- Kawalec et al. (2013) (opens in a new tab)
- Khalid and Hitch (2025) (opens in a new tab)
- Kim et al. (2014) (opens in a new tab)
- Kinaciyan et al. (2026) (opens in a new tab)
- Kutrieb et al. (2026) (opens in a new tab)
- Leibovich-Nassi et al. (2023) (opens in a new tab)
- Lesage et al. (2020) (opens in a new tab)
- Lesage et al. (2021) (opens in a new tab)
- Lesage et al. (2022) (opens in a new tab)
- Lesage et al. (2026a) (opens in a new tab)
- Lesage et al. (2026b) (opens in a new tab)
- Leung et al. (2026) (opens in a new tab)
- Levy et al. (2010) (opens in a new tab)
- Li et al. (2023) (opens in a new tab)
- Li et al. (2025) (opens in a new tab)
- Lo et al. (2022) (opens in a new tab)
- Lochbaum et al. (2026) (opens in a new tab)
- Longhurst et al. (2024) (opens in a new tab)
- Lu et al. (2020) (opens in a new tab)
- Lumry et al. (2010) (opens in a new tab)
- Lumry et al. (2011) (opens in a new tab)
- Lumry et al. (2025) (opens in a new tab)
- Maurer et al. (2013) (opens in a new tab)
- Maurer et al. (2022) (opens in a new tab)
- Maurer et al. (2023a) (opens in a new tab)
- Maurer et al. (2023b) (opens in a new tab)
- Maurer et al. (2026) (opens in a new tab)
- McMillan et al. (2012) (opens in a new tab)
- MedlinePlus (opens in a new tab)
- Meisgen et al. (2026) (opens in a new tab)
- Mendivil et al. (2021) (opens in a new tab)
- Mendivil et al. (2026) (opens in a new tab)
- Minafra et al. (2022a) (opens in a new tab)
- Minafra et al. (2022b) (opens in a new tab)
- MO HealthNet Ekterly fact blast (2025) (opens in a new tab)
- NICE sebetralstat draft guidance (2025) (opens in a new tab)
- NICE sebetralstat project page (2026) (opens in a new tab)
- O'Connor et al. (2025) (opens in a new tab)
- Olson et al. (2026) (opens in a new tab)
- Onderzoekmetmensen.nl NL-OMON49496 (opens in a new tab)
- Onderzoekmetmensen.nl NL-OMON49587 (opens in a new tab)
- Petersen et al. (2024) (opens in a new tab)
- Pharming RUCONEST prescribing information (2020) (opens in a new tab)
- Pharvaris 2025 strategic priorities press release (2025) (opens in a new tab)
- Pharvaris 2026 strategic priorities press release (2026) (opens in a new tab)
- Pharvaris AAAAI 2026 press release (2026) (opens in a new tab)
- Pharvaris ACAAI 2020 press release (2020) (opens in a new tab)
- Pharvaris CIIC Spring 2026 press release (2026) (opens in a new tab)
- Pharvaris clinical hold press release (2022) (opens in a new tab)
- Pharvaris corporate presentation, January 2024 (2024) (opens in a new tab)
- Pharvaris EAACI 2026 press release (2026) (opens in a new tab)
- Pharvaris Form 20-F (2026) (opens in a new tab)
- Pharvaris Form 6-K, first quarter 2025 results (2025) (opens in a new tab)
- Pharvaris Form 6-K, first quarter 2026 results (2026) (opens in a new tab)
- Pharvaris Form 6-K, fourth quarter and full year 2025 results (2026) (opens in a new tab)
- Pharvaris Form 6-K, second quarter 2025 results (2025) (opens in a new tab)
- Pharvaris Form 6-K, second quarter 2026 results (2026) (opens in a new tab)
- Pharvaris Form 6-K, third quarter 2026 MD&A (2026) (opens in a new tab)
- Pharvaris Form 6-K, third quarter 2026 results (2026) (opens in a new tab)
- Pharvaris Form F-1/A registration statement (2021) (opens in a new tab)
- Pharvaris NDA acceptance press release (2026) (opens in a new tab)
- Pharvaris RAPIDe-1 topline press release (2022) (opens in a new tab)
- Pharvaris RAPIDe-3 Lancet publication press release (2026) (opens in a new tab)
- Pharvaris RAPIDe-3 topline data presentation (2025) (opens in a new tab)
- Pharvaris RAPIDe-3 topline press release (2025) (opens in a new tab)
- Pharvaris RAPIDe-3 topline timing update press release (2025) (opens in a new tab)
- Princic et al. (2025) (opens in a new tab)
- Regence medication policy dru535 (2026) (opens in a new tab)
- Riedl et al. (2014) (opens in a new tab)
- Riedl et al. (2018) (opens in a new tab)
- Riedl et al. (2023a) (opens in a new tab)
- Riedl et al. (2023b) (opens in a new tab)
- Riedl et al. (2023c) (opens in a new tab)
- Riedl et al. (2024) (opens in a new tab)
- Riedl et al. (2026a) (opens in a new tab)
- Riedl et al. (2026b) (opens in a new tab)
- Riedl et al. (2026c) (opens in a new tab)
- Sandberg et al. (2024) (opens in a new tab)
- Shah et al. (2023) (opens in a new tab)
- Sundler Björkman et al. (2022) (opens in a new tab)
- Tachdjian et al. (2024) (opens in a new tab)
- Tachdjian et al. (2026) (opens in a new tab)
- Takeda FIRAZYR prescribing information (2024) (opens in a new tab)
- Takeda KALBITOR prescribing information (2020) (opens in a new tab)
- Troelnikov et al. (2024) (opens in a new tab)
- Univera Healthcare hereditary angioedema pharmacy policy (2026) (opens in a new tab)
- US Hereditary Angioedema Association (opens in a new tab)
- US Hereditary Angioedema Association treatment guidelines (opens in a new tab)
- Valerieva et al. (2023) (opens in a new tab)
- Valerieva et al. (2024) (opens in a new tab)
- Vázquez et al. (2026) (opens in a new tab)
- Vernon et al. (2009) (opens in a new tab)
- Watt et al. (2026a) (opens in a new tab)
- Watt et al. (2026b) (opens in a new tab)
- Wilson et al. (2010) (opens in a new tab)
- Wong et al. (2022) (opens in a new tab)
- World Health Organization (2021) (opens in a new tab)
- Yong et al. (2023) (opens in a new tab)
- Yong et al. (2025) (opens in a new tab)
- Zanichelli et al. (2015) (opens in a new tab)
- Zhang et al. (2025) (opens in a new tab)
- Zilberberg et al. (2010) (opens in a new tab)
- Zilberberg et al. (2011) (opens in a new tab)
- Zuraw and Christiansen (2026) (opens in a new tab)
- Zuraw et al. (2010) (opens in a new tab)